Apolipoprotein B, Imaging Resolution, and the Illusion of “Normal” Coronary Arteries at Age 60
The clinical assertion that individuals maintaining markedly elevated levels of low-density lipoproteinA lipoprotein is a tiny package that carries fat and cholesterol through your bloodstream. Since fat won't dissolve in water, it needs a protein wrapper to travel. cholesterolCholesterol is a waxy substance your body needs. It goes into cell walls, hormones, vitamin D, and the bile that digests your food. You would die without it. (LDL-C) and apolipoproteinAn apolipoprotein is a protein attached to a fat-carrying particle in your blood. Fat and water don't mix, so these proteins act like a wrapper that lets fat travel safely through the bloodstream. B (ApoBApoB is a protein that sits on the outside of every cholesterol particle that can get stuck in your artery wall and cause plaque. Each of those particles carries exactly one ApoB.) can possess anatomically “normal” coronary arteriesThe coronary arteries are the small vessels that wrap around the outside of your heart and feed the heart muscle itself. at age 60 represents a diagnostic paradox. This phenomenon often hinges on the resolution of the imaging tool used. While contemporary tools like the Coronary Artery Calcium (CAC)Coronary artery calcium is a measure of calcified plaque deposits in the walls of the coronary arteries, quantified by CT scan and expressed as an Agatston score; higher scores indicate greater cumulative plaque burden and predict future cardiovascular events. score and standard visual Coronary Computed TomographyComputed tomography, or CT, takes X-ray images from many angles and reconstructs them into cross-sections of the body. Angiography (CCTA) provide a high-resolution window into the arterial wall, they exist in tension with pathological evidence which suggests that atherosclerosisAtherosclerosis is the disease behind most heart attacks and many strokes. Cholesterol particles get stuck in the wall of an artery, the body sends immune cells to clean up, and over years that mess hardens into plaque. is a nearly universal condition of human aging, and clinical data showing that heart attacksA heart attack happens when blood flow to part of the heart muscle is cut off and that muscle starts to die. can occur even in the absence of significant anatomical blockages [1].
The Causal Framework of Lipoprotein-Driven Atherogenesis
The consensus establishes that prolonged exposure to ApoB-containing lipoproteins is the primary driver of atherosclerotic plaquePlaque is the buildup of cholesterol, immune cells, scar tissue, and calcium inside an artery wall. [2]. Each atherogenic particleAtherogenic particles are the ApoB-containing lipoproteins—including LDL, IDL, VLDL, and lipoprotein(a)—that can enter and be retained in the artery wall to initiate and sustain plaque growth; the article uses the term to describe what must be lowered substantially and sustainably to achieve plaque regression.—including LDLLDL, or low-density lipoprotein, is the main particle that carries cholesterol through your blood — and the main one that gets stuck in artery walls., VLDLVLDL, or very-low-density lipoprotein, is the particle your liver makes to ship triglycerides out to the rest of the body., and IDLIDL, or intermediate-density lipoprotein, is a particle that forms partway through the process of a big triglyceride-carrying particle shrinking down into an LDL particle.—carries a single molecule of ApoB, making it a direct measure of the total number of circulating particles that can penetrate the arterial wall [2]. The probability of a particle becoming trapped in the subendothelial spaceThe subendothelial space is the narrow gap just beneath the artery's inner lining, between that single layer of cells and the muscle beneath. is a function of both particle concentration and the duration of exposure, often quantified as “ApoB-yearsApoB-years is a proposed research metric that represents cumulative apolipoprotein B exposure over time, expressed as the area under the apoB-versus-age curve in mg/dL·years; it is intended to capture integrated atherogenic particle burden more directly than any single measurement, but has not yet been validated as a clinical tool or treatment threshold.” [2].
While LDL-C measures the mass of cholesterol, ApoB reflects the particle burdenParticle burden refers to the total number of atherogenic lipoprotein particles circulating in the plasma, best measured by ApoB; it is distinguished from cholesterol mass because it is the physical count of particles — not the amount of cholesterol they carry — that determines how frequently lipoproteins infiltrate and become entrapped in the arterial wall. [3]. In cases of discordanceSee ApoB Discordance for the full entry.—where ApoB is high but LDL-C is relatively lower—ApoB remains the more accurate predictor of future myocardial infarctionSee Heart Attack for the full entry. (MI) and clinical events [4].
Lipoprotein Metrics
| Lipoprotein Metric | Definition and Pathological Role | Association with Plaque BurdenPlaque burden is the total amount of plaque in your arteries, everywhere — not just at the single worst spot. |
| Low-Density Lipoprotein Cholesterol (LDL-C) | The mass of cholesterol contained within LDL particles | Causal, but may be discordant with particle count [3] |
| Apolipoprotein B (ApoB) | A structural proteinProtein is the nutrient your body uses to build and repair muscle and tissue.; one exists on every atherogenic particle | Strongest predictor of risk; reflects true particle burden [3] |
| Lipoprotein(a)Lipoprotein(a), written Lp(a) and said "L-P-little-a," is an LDL-like particle with an extra sticky protein attached. [Lp(a)] | An LDL-like particle with an additional protein [apo(a)] | Independent risk factorA risk factor is something that raises your chance of developing a disease — high cholesterol particles, high blood pressure, smoking, diabetes, family history.; promotes calcificationCalcification is when calcium gets deposited into a plaque, turning part of it hard and bony. and thrombosisThrombosis is a blood clot forming inside a blood vessel. [5] |
Forensic vs. Clinical Reality: The “Pristine” Artery Illusion
The claim that an individual can reach age 60 without “arterial damage” is often a result of clinical imaging failing to detect microscopic disease. Forensic autopsy studies, including the Pathobiological Determinants of Atherosclerosis in Youth (PDAYPDAY, short for Pathobiological Determinants of Atherosclerosis in Youth, examined the arteries of young people aged 15 to 34 who died of other causes.) and the Bogalusa Heart StudyThe Bogalusa Heart Study examined the arteries of children and young adults who died in accidents in a Louisiana town., demonstrate that microscopic fatty streaksA fatty streak is the earliest visible stage of atherosclerosis — a flat yellow smear of cholesterol-filled immune cells just under the artery lining.—the earliest macroscopic evidence of atherosclerosis—are present in nearly all adolescents examined [6].
By the sixth decade of life, pathologically pristine coronary arteries are virtually absent in Westernized populations. Diffuse intimal thickeningIntimal thickening is an early adaptive or pathological increase in the thickness of the innermost layer of an artery (the intima), which can reflect either normal developmental changes or the accumulation of smooth muscle cells, lipids, and inflammatory cells that precede overt plaque formation. It is measurable non-invasively by carotid intima-media thickness ultrasound. and lipid deposition become ubiquitous by midlife, and contemporary autopsy cohorts report coronary atherosclerosis in nearly all adults by the fourth decade [6].
The Glagov Effect: How Arteries Hide Plaque Burden
A critical contributor to “normal” coronary imagingNon-invasive or invasive techniques—such as quantitative coronary angiography or intravascular ultrasound—used to visualise the size and character of plaques inside the coronary arteries; the Ornish and Esselstyn work is notable for using objective coronary imaging rather than relying solely on symptom or event data. is the Glagov phenomenonThe Glagov phenomenon (also called compensatory or outward remodeling) is the tendency of an arterial wall to expand outward as atherosclerotic plaque accumulates, thereby preserving the inner lumen diameter until plaque burden becomes very large. Because lumen size stays normal during this compensatory phase, standard stress tests and angiograms can appear normal even in the presence of substant…, or compensatory outward remodelingThe process by which an artery expands its outer diameter to preserve luminal blood flow as plaque accumulates within the vessel wall; luminal narrowing is typically delayed until plaque occupies roughly 40% of the internal elastic lamina area, making early disease invisible to lumen-focused imaging. [7]. As plaque accumulates within the arterial wall, the vessel expands externally to preserve luminal diameter and maintain blood flow [7]. Hemodynamically significant luminal narrowing is typically delayed until plaque burden exceeds approximately 40% of the internal elastic lamina area [7].
Because standard invasive angiography and conventional visual CCTA focus primarily on the lumenThe lumen is the open channel inside a blood vessel where blood actually flows., substantial plaque burden may exist within the vessel wall while remaining angiographically invisible [7]. These concealed plaques are often lipid-rich and biologically active, rendering them prone to erosion or rupture capable of precipitating MI even in the absence of pre-existing stenosisStenosis is narrowing — usually described as a percentage, like a 70 percent blockage. [1].
AI-QCT (Cleerly) vs. Standard Visual Interpretation
Artificial Intelligence–Quantitative Computed Tomography (AI-QCT) platforms, such as Cleerly, have demonstrated that standard visual interpretation of CCTA systematically underestimates plaque burden [8]. By enabling volumetric plaque quantificationA computational technique, employed by AI-QCT platforms such as Cleerly, that measures the three-dimensional volume and composition of coronary plaque from CT data rather than relying on visual estimation of lumen narrowing. and compositional analysis, AI-QCT achieves accuracy approaching invasive intravascular ultrasoundIntravascular ultrasound, or IVUS, uses a tiny ultrasound probe threaded inside a coronary artery to photograph the wall from within. [8].
In a cohort of approximately 750 patients, AI-QCT analysis led to diagnostic modification in 39% of cases, while the number of patients classified as having “no plaque” fell from 159 to 58 following quantitative assessment [8]. These findings confirm that visually “normal” coronary CT angiogramsAn angiogram is a test where doctors thread a thin tube into your arteries and inject dye, so the inside of the arteries shows up on an X-ray. frequently harbor clinically relevant non-calcified plaqueNon-calcified plaque is the soft, fatty portion of a plaque that has not hardened with calcium. It shows up dark on a CT scan..
Coronary Artery Calcium Score and Myocardial Infarction Risk
Coronary ArteryAn artery is a blood vessel that carries blood away from the heart to the rest of the body. Calcium scoring is a powerful population-level risk stratification tool, but its relationship with individual myocardial infarction risk is probabilistic rather than absolute. Large prospective cohortsA prospective cohort enrolls healthy people, records their characteristics, and then waits to see what happens., including the Multi-Ethnic Study of Atherosclerosis (MESA)A large prospective cohort study of adults initially free of cardiovascular disease that has provided foundational data on coronary artery calcium scoring, demonstrating a strong graded association between CAC burden and future coronary events and validating the risk implications of a CAC score of zero., demonstrate a strong graded association between CAC burden and future coronary heart diseaseCoronary heart disease is the narrowing or blockage of the arteries that supply blood to the heart muscle, caused by the buildup of atherosclerotic plaque; it is the leading cause of heart attack and cardiac death worldwide. events, with markedly elevated risk observed at scores ≥300 [11].
However, a CAC score of zero does not confer immunity from MI. Although short-term event rates are low, non-calcified, lipid-rich plaquesAn atherosclerotic lesion whose core is dominated by cholesterol esters and inflammatory lipids rather than calcium or fibrous tissue; the article notes that such plaques are highly responsive to intensive treatment and that the dramatic 65-percentage-point regression at the diagonal branch origin is consistent with reversal of a lipid-rich lesion.—particularly in individuals with elevated ApoB—remain capable of rupture or erosion [12]. Approximately 25–30% of acute coronary syndromesAcute coronary syndrome (ACS) is the umbrella term for any sudden drop in blood flow to the heart — from unstable angina to a full heart attack — caused by a plaque suddenly rupturing or eroding. occur in individuals with absent or minimal coronary calcification at baseline, reflecting the temporal disconnect between plaque formation, calcification, and plaque instability [12]. Calcification is increasingly recognized as a marker of plaque chronicityThe concept that calcification within atherosclerotic plaque reflects older, more stable disease that has undergone fibrous and calcium deposition over time, rather than active, vulnerable disease; it is why high calcium scores indicate cumulative long-term burden rather than imminent rupture risk. and healing rather than vulnerability, whereas non-calcified plaque burden correlates more closely with near-term risk.
Thus, CAC scoring is best interpreted as a measure of cumulative plaque burden and long-term risk rather than as a detector of biologically active atherosclerosis. In high–ApoB individuals, a CAC score of zero more likely reflects delayed disease expression than true disease absence.
MI Risk With “Near-Zero” Plaque Burden: The MINOCA Syndrome
Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA) accounts for approximately 5–15% of all acute myocardial infarctions [1]. Even small, non-obstructive plaquesAtherosclerotic plaque that occupies less than 50% of the coronary artery lumen, allowing blood to flow normally and typically producing no symptoms on standard stress testing; it is nonetheless the source of the majority of myocardial infarctions when it ruptures. may undergo endothelial erosion, triggering localized thrombosis without angiographically visible obstruction [9].
Importantly, ApoB remains a strong independent predictorA variable that statistically forecasts an outcome—such as mortality—even after accounting for other known risk factors like age, BMI, and cholesterol through multivariable analysis. of MI risk even among individuals without obstructive coronary disease, as demonstrated in large population cohorts and randomized lipid-lowering trials [4].
Longitudinal Data: Prevalence of Zero Plaque From 60 to 100 Years
Despite near-universal atherosclerosis on pathological examination, clinical imaging registries identify a subset of individuals who maintain zero coronary calcification into advanced age [10].
| Age Group (Years) | Prevalence of CAC = 0 (Clinical Imaging) | Likelihood of Truly “Pristine” Arteries (Autopsy) |
| 61–75 | 28%–40% | ~0% |
| 75–85 | 10%–20% | ~0% |
| ≥90 | ~5% | ~0% |
In the oldest old, a so-called “cholesterol paradox” has been observed, wherein higher LDL-C levels (≥130 mg/dL) are sometimes associated with longer survival, likely reflecting survival bias or age-dependent protective roles of cholesterol in immune function and cellular repair [10].
References
- Tamis-Holland JE, Jneid H, Reynolds HR, et al. Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the American Heart Association. Circulation. 2019;139(18):e891-e908. doi:10.1161/CIR.0000000000000670
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144
- Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019;4(12):1287-1295. doi:10.1001/jamacardio.2019.3780
- Marston NA, Giugliano RP, Melloni GEM, et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content. JAMA Cardiol. 2022;7(3):250-256. doi:10.1001/jamacardio.2021.5083
- Tsimikas S. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69(6):692-711. doi:10.1016/j.jacc.2016.11.042
- Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA. 1999;281(8):727-735. doi:10.1001/jama.281.8.727
- Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316(22):1371-1375. doi:10.1056/NEJM198705283162204
- Nurmohamed NS, Cole JH, Budoff MJ, et al. Impact of atherosclerosis imaging-quantitative computed tomography on diagnostic certainty, downstream testing, coronary revascularization, and medical therapy: the CERTAIN study. Eur Heart J Cardiovasc Imaging. 2024;25(6):857-866. doi:10.1093/ehjci/jeae029
- Agewall S, Beltrame JF, Reynolds HR, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017;38(3):143-153. doi:10.1093/eurheartj/ehw149
- Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70-100 years: a contemporary primary prevention cohort. Lancet. 2020;396(10263):1644-1652. doi:10.1016/S0140-6736(20)32233-9
- Budoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49(18):1860-1870. doi:10.1016/j.jacc.2006.10.079
- Blaha MJ, Cainzos-Achirica M, Greenland P, et al. Role of Coronary Artery Calcium Score of Zero and Other Negative Risk Markers for Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2016;133(9):849-858. doi:10.1161/CIRCULATIONAHA.115.018524

